Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–2390.

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–2390.)| false
• Search Google Scholar
• Export Citation

Csaba Bödör AG. Tamás Schneider Diffúz nagy B-sejtes lymphoma: úton a személyre szabott terápia felé. Klinikai Onkológia 2017; 4. évf. 1. szám.

Csaba Bödör AG. Tamás Schneider Diffúz nagy B-sejtes lymphoma: úton a személyre szabott terápia felé. Klinikai Onkológia 2017; 4. évf. 1. szám.)| false
• Search Google Scholar
• Export Citation

Bödör C, Reiniger L. Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. Cancer Metastasis Rev 2016; 35: 109–127.

Bödör C, Reiniger L. Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. Cancer Metastasis Rev 2016; 35: 109–127.)| false
• Search Google Scholar
• Export Citation

Wang L, Li L-R, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol 2020; 13.

Wang L, Li L-R, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol 2020; 13.)| false
• Search Google Scholar
• Export Citation

Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.

Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.)| false
• Search Google Scholar
• Export Citation

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.)| false
• Search Google Scholar
• Export Citation

Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123: 1214–1217.

Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123: 1214–1217.)| false
• Search Google Scholar
• Export Citation

Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 2019; 20: 649–662.

Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 2019; 20: 649–662.)| false
• Search Google Scholar
• Export Citation

Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019; 37: 1285–1295.

Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019; 37: 1285–1295.)| false
• Search Google Scholar
• Export Citation

Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021; 39: 1317–1328.

Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021; 39: 1317–1328.)| false
• Search Google Scholar
• Export Citation

Sha C, Barrans S, Cucco F, et al. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol 2019; 37: 202–212.

Sha C, Barrans S, Cucco F, et al. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol 2019; 37: 202–212.)| false
• Search Google Scholar
• Export Citation

Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood 2019; 134: 1528–1532.

Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood 2019; 134: 1528–1532.)| false
• Search Google Scholar
• Export Citation

Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24: 679–690.

Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24: 679–690.)| false
• Search Google Scholar
• Export Citation

Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018; 378: 1396–1407.

Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018; 378: 1396–1407.)| false
• Search Google Scholar
• Export Citation

Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020; 37: 551–568 e514.

Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020; 37: 551–568 e514.)| false
• Search Google Scholar
• Export Citation

Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol 2022; 196: 814–829.

Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol 2022; 196: 814–829.)| false
• Search Google Scholar
• Export Citation

Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 2016; 8: 364ra155.

Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 2016; 8: 364ra155.)| false
• Search Google Scholar
• Export Citation

Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol 2022; 40: 585–597.

Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol 2022; 40: 585–597.)| false
• Search Google Scholar
• Export Citation

Moia RFC, Talotta D, Sagiraju S, et al. P1281: liquid BIOPSY provides complementary information to tissue biopsies for the molecular classification of DLBCL patients. Hemasphere 2022: 1166–1167.

Moia RFC, Talotta D, Sagiraju S, et al. P1281: liquid BIOPSY provides complementary information to tissue biopsies for the molecular classification of DLBCL patients. Hemasphere 2022: 1166–1167.)| false
• Search Google Scholar
• Export Citation

Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018; 36: 2845–2853.

Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018; 36: 2845–2853.)| false
• Search Google Scholar
• Export Citation

Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Translational Med 2016; 8: 364ra155-364ra361.

Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Translational Med 2016; 8: 364ra155-364ra361.)| false
• Search Google Scholar
• Export Citation

Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018; 36: 2845–2853.

Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018; 36: 2845–2853.)| false
• Search Google Scholar
• Export Citation

Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 2021; 39: 1537–1547.

Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 2021; 39: 1537–1547.)| false
• Search Google Scholar
• Export Citation

Kurtz DM, Esfahani MS, Scherer F, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 2019; 178: 699–713 e619.

Kurtz DM, Esfahani MS, Scherer F, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 2019; 178: 699–713 e619.)| false
• Search Google Scholar
• Export Citation

Mikhaeel NG, Heymans MW, Eertink JJ, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol 2022; 40: 2352–2360.

Mikhaeel NG, Heymans MW, Eertink JJ, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol 2022; 40: 2352–2360.)| false
• Search Google Scholar
• Export Citation

Pajor L, Kun J, Herczeg R, et al. A diffúz nagy B-sejtes limfóma fenotipikus, citogenetikai és expressziós profil heterogenitása – magyarországi multicentrikus tanulmány. Hematológia–Transzfuziológia 2023; 55: 154–163.

Pajor L, Kun J, Herczeg R, et al. A diffúz nagy B-sejtes limfóma fenotipikus, citogenetikai és expressziós profil heterogenitása – magyarországi multicentrikus tanulmány. Hematológia–Transzfuziológia 2023; 55: 154–163.)| false
• Search Google Scholar
• Export Citation

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720–1748.

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720–1748.)| false
• Search Google Scholar
• Export Citation

Laura Kiss BB, Csaba Bödör, Ákos Nagy. Új molekuláris klasszifikációs rendszerek diffúz nagy B-sejtes limfómában. Hematológia - Transzfuziológia 2021; 54: 104–112.

Laura Kiss BB, Csaba Bödör, Ákos Nagy. Új molekuláris klasszifikációs rendszerek diffúz nagy B-sejtes limfómában. Hematológia - Transzfuziológia 2021; 54: 104–112.)| false
• Search Google Scholar
• Export Citation